These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18183661)

  • 1. San Antonio Breast Cancer Symposium.
    Collingridge D
    Lancet Oncol; 2008 Jan; 9(1):14. PubMed ID: 18183661
    [No Abstract]   [Full Text] [Related]  

  • 2. San Antonio Breast Cancer Symposium.
    Fricker J
    Lancet Oncol; 2009 Jan; 10(1):20. PubMed ID: 19115517
    [No Abstract]   [Full Text] [Related]  

  • 3. Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient.
    Pizzuti L; Sergi D; Barba M; Vici P
    Tumori; 2013; 99(3):e127-30. PubMed ID: 24158082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer.
    Cottu PH; Asselah J; Lae M; Pierga JY; Diéras V; Mignot L; Sigal-Zafrani B; Vincent-Salomon A
    Ann Oncol; 2008 Mar; 19(3):595-7. PubMed ID: 18272907
    [No Abstract]   [Full Text] [Related]  

  • 5. HER-2-positive metastatic breast cancer: trastuzumab and beyond.
    Metro G; Mottolese M; Fabi A
    Expert Opin Pharmacother; 2008 Oct; 9(15):2583-601. PubMed ID: 18803447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib in locally advanced or metastatic breast cancer.
    Gradishar WJ
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1177-91. PubMed ID: 22616580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
    Verma S; Ilersich AL
    Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subdural collections arising from calvarial metastases following discontinuation of anti-angiogenic therapy.
    Wong AL; Chou N; Lee KM; Ang BW; Cheng CL; Lee SC
    Ann Oncol; 2009 Sep; 20(9):1605-1606. PubMed ID: 19622509
    [No Abstract]   [Full Text] [Related]  

  • 9. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
    Michalaki V; Fotiou S; Gennatas S; Gennatas C
    Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
    Guarneri V
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1549-57. PubMed ID: 19895239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
    Bartsch R; Wenzel C; Altorjai G; Pluschnig U; Rudas M; Mader RM; Gnant M; Zielinski CC; Steger GG
    J Clin Oncol; 2007 Sep; 25(25):3853-8. PubMed ID: 17679724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
    von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
    J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
    J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current combination chemotherapy regimens for metastatic breast cancer.
    Schwartz J
    Am J Health Syst Pharm; 2009 Dec; 66(23 Suppl 6):S3-8. PubMed ID: 19923317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
    Kataoka M; Yamaguchi Y; Moriya Y; Sawada N; Yasuno H; Kondoh K; Evans DB; Mori K; Hayashi S
    Oncol Rep; 2012 Feb; 27(2):303-10. PubMed ID: 22076074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available.
    Bianchi GV; Duca M; Sica L; Mariani G
    Tumori; 2013; 99(6):269e-72e. PubMed ID: 24503801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Docetaxel (Taxotere) in combination with anthracycline, capecitabin (Xeloda) and new drugs].
    Galligioni E
    Tumori; 2001; 87(1 Suppl 2):S1-9. PubMed ID: 11357871
    [No Abstract]   [Full Text] [Related]  

  • 18. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer.
    De Iuliis F; Salerno G; Taglieri L; Lanza R; Scarpa S
    Tumori; 2015; 101(1):30-5. PubMed ID: 25702645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
    Thomas ES
    J Clin Oncol; 2008 May; 26(13):2223. PubMed ID: 18445853
    [No Abstract]   [Full Text] [Related]  

  • 20. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
    J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.